Red List
KROS
Keros Therapeutics, Inc.
Healthcare · Biotechnology · small-cap ($336M)
-51.3%
from rolling 252-day high of $22.55 set 2025-12-08 · 157d ago
Current
$10.99
Decline depth
-51.3%
Decline σ
5.3σ
TFC
2/5 bearish
Rolling 252-day high Up day Down day Last 90 trading days · data from Alpaca

Structural break signals

KROS qualifies for the Red List on decline depth.

Decline depth
-51.3%
From rolling 252-day high of $22.55, 157d ago. Past the 40% Red List threshold.
Time-frame continuity
2/5 bearish
Latest bar across daily/weekly/monthly/quarterly/yearly time frames. A bar counts as bearish when it's a 2-Down or a red 3.
Decline sigma
5.3σ
Drop from local high over the last 5 bars, expressed in units of the stock's typical daily volatility (2.93% per day). Past the ≥4σ Watch threshold.

The structural read

What price action says about KROS.

KROS qualifies for the Red List on decline depth — down -51.3% from its rolling 252-day high. Past the 40% threshold, the deepest tier in the taxonomy.

Cross-confirmation: decline sigma also reads 5.3σ over 5 bars.

Earnings on file: 2026-03-04. Tiering is unaffected by earnings dates — listings reflect price structure only.

52-week range

52W low $9.12 13.9% of range 52W high $22.55

Sector context · Healthcare

182 other Healthcare tickers are on Broken Stocks.

92 Red List
43 Amber
47 Watch
-35.8% Median decline

Worst in sector: OPRX (-76.7%). Least-bad: ANIP (-20.0%). See all Healthcare listings →

Questions about KROS

What people ask.

Why is KROS on Broken Stocks?

KROS qualifies for the Red List on decline depth. It is down -51.3% from its rolling 252-day high of $22.55, set on 2025-12-08 — 157d ago.

Is KROS a falling knife?

Not by the strict technical definition. KROS is down -51.3% from its 52-week high, but that high was set 157d ago — more than 120 days. A falling knife is usually a recent breakdown from a fresh high, not an established multi-quarter downtrend. KROS is still on the Red List for decline depth, but the freshness component of a falling knife is missing.

Is KROS a buy?

Broken Stocks does not issue buy or sell recommendations. The list is a rules-based technical warning system. It tracks structural decline depth and recency — not company quality, management, fundamentals, or news. Always do your own research and consult a licensed advisor.

Where is KROS trading inside its 52-week range?

At $10.99, KROS sits 13.9% of the way from its 52-week low ($9.12) to its 52-week high ($22.55). A reading below 25% indicates price is hugging the bottom of the range; above 75%, the top.

How fast has KROS been declining?

The current 51.3% decline accrued over 157d, which annualizes to roughly -119.3% per year. Annualized pace is a sanity check — a 30% decline in three months is a different signal than a 30% decline over two years.

How does KROS compare to its sector?

There are 182 other Healthcare tickers on Broken Stocks: 92 Red, 43 Amber, 47 Watch, with 55 showing recovering structural signals. Median sector decline is -35.8% — KROS's decline is deeper than the sector median.

Does KROS's earnings date affect its tier?

No. Tiering is decided purely by decline depth and recency of the rolling-high date. The earnings date on file (2026-03-04) is shown for reference only — listings can move tier between scans based on closing prices, regardless of fundamentals or news events.